Linc

Linc EBIT Growth

The Year-over-Year EBIT Growth of Linc (LINC.ST) as of Nov 20, 2026 is -133.11 %. In the previous year, Year-over-Year EBIT Growth was 96.87 % — a change of -237.41% (lower).

EBIT Growth

-133.11 %

YoY

-237.41%

Last updated:

Year-over-Year EBIT Growth of Linc is 2025 -133.11 % . Year-over-Year EBIT Growth of Linc was 2024 96.87 % . It decreases by -237.41% lower compared to the previous year.

The Linc EBIT Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Growth
Date
EBIT Growth
Jan 1, 2019
98.01 SEK
Jan 1, 2020
61.07 SEK
Jan 1, 2021
-103.83 SEK
Jan 1, 2022
-2,318.83 SEK
Jan 1, 2023
172.20 SEK
Jan 1, 2024
96.87 SEK
Jan 1, 2025
-133.11 SEK
The Linc EBIT Growth history
YEAREBIT GrowthYoY
-133.11 %-237.41%
96.87 %-43.75%
172.20 %-107.43%
-2,318.83 %+2,133.32%
-103.83 %-270.01%
61.07 %-37.69%
98.01 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Linc Stock analysis

What does Linc do? Linc AB generates revenue through long-term share ownership in Nordic life science companies, focusing on pharmaceutical and medical technology sectors. The company invests in both private and public firms, including early-stage drug development and operational medical technology companies. Linc Invest actively supports portfolio companies by collaborating with management, founders, and boards to unlock growth potential and drive expansion. Its industrial network enables strategic participation in nomination committees and development planning. The firm targets Nordic life science product-oriented companies, prioritizing pharmaceuticals and medical technology. Investments span research and operational phases, with drug development typically occurring earlier than in medical technology. Linc AB maintains a hands-on approach as a long-term owner, leveraging its network to assist portfolio companies in achieving ambitious development goals. Linc AB's business model centers on active ownership and strategic partnerships within the Nordic life science ecosystem. It focuses on companies with strong product pipelines, particularly in pharmaceuticals, where investments often occur during initial development stages. The company's role as a supportive shareholder drives value creation through collaborative governance and targeted expansion strategies. Linc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Linc stock

Year-over-Year EBIT Growth of Linc is -133.11 % in 2025.

On Eulerpool you can find the complete historical development of Year-over-Year EBIT Growth Linc since 2006 – with annual values, charts, and detailed analysis.

EBIT growth measures the percentage change in operating earnings. It shows whether a company's core operations are becoming more profitable.

To evaluate Year-over-Year EBIT Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBIT Growth.

Year-over-Year EBIT Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBIT Growth's Linc historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Linc

All Key Metrics — Linc